Latest Breaking News On - Neximmune inc - Page 8 : vimarsana.com

NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

A JDRF funded grant is being used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md.,.

United statesKristi jonesKevan heroldNeximmune incExchange commissionChief executive officerArtificial immune modulationPrivate securities litigation reform actNasdaq capital marketAnnual report

NexImmune Announces Presentations at The Society for Immunotherapy of Cancer s 38th Annual Meeting

NexImmune Announces Presentations at The Society for Immunotherapy of Cancer s 38th Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesBryan hahnRui wangLauren suarezJack raghebDurgadas cherukaraveeduSojung kimBrian alvarezHaiyun liuDuong nguyenRuipeng wangCharles reedKristi jonesAniket wadajkarJerome zeldis

NexImmune (NEXI) Announces 1-for-25 Reverse Stock Split

NexImmune (NEXI) Announces 1-for-25 Reverse Stock Split
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Computershare trust companyNeximmune incNasdaq capital marketNasdaq capital

NexImmune Announces 1-for-25 Reverse Stock Split

NexImmune Announces 1-for-25 Reverse Stock Split
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Computershare trust companyExchange commissionNeximmune incNasdaq capital marketNasdaq capitalArtificial immune modulationPrivate securities litigation reform actAnnual report

NexImmune, Inc (NASDAQ:NEXI) Sees Significant Increase in Short Interest

NexImmune, Inc. (NASDAQ:NEXI – Get Free Report) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 134,900 shares, a growth of 21.3% from the September 15th total of 111,200 shares. Based on an average daily volume of 83,300 shares, the […]

Neximmune incRaymond james associatesRenaissance technologiesVanguard group incSei investments coGet free reportStreet corpVanguard groupArtificial immune modulationNeximmune dailyNasdaq nexi